The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Wilfried De Backer, Wim Vos, Cedric Van Holsbeke, Samir Vinchurkar, Rita Claes, Annemie Hufkens, Paul M. Parizel, Lieven Bedert, Jan De Backer
European Respiratory Journal 2014; DOI: 10.1183/09031936.00011714
Wilfried De Backer
1Dept of Respiratory Medicine, University Hospital Antwerp, Antwerp, Belgium,
Wim Vos
2Fluidda nv, Kontich, Belgium,
Cedric Van Holsbeke
2Fluidda nv, Kontich, Belgium,
Samir Vinchurkar
2Fluidda nv, Kontich, Belgium,
Rita Claes
1Dept of Respiratory Medicine, University Hospital Antwerp, Antwerp, Belgium,
Annemie Hufkens
1Dept of Respiratory Medicine, University Hospital Antwerp, Antwerp, Belgium,
Paul M. Parizel
3Dept of Radiology, University Hospital Antwerp, Antwerp, Belgium,
Lieven Bedert
4Dept of Respiratory Medicine, ZNA Middelheim Hospital, Antwerp, Belgium,
Jan De Backer
2Fluidda nv, Kontich, Belgium,

Abstract
COPD patients prone to dynamic hyperinflation tend to benefit from roflumilast due to change in airflow distribution http://ow.ly/v6S0O
- Received January 15, 2014.
- Accepted March 12, 2014.
- © ERS
Vol 61 Issue 4
Table of Contents
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Wilfried De Backer, Wim Vos, Cedric Van Holsbeke, Samir Vinchurkar, Rita Claes, Annemie Hufkens, Paul M. Parizel, Lieven Bedert, Jan De Backer
European Respiratory Journal Jan 2014, erj00117-2014; DOI: 10.1183/09031936.00011714
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Wilfried De Backer, Wim Vos, Cedric Van Holsbeke, Samir Vinchurkar, Rita Claes, Annemie Hufkens, Paul M. Parizel, Lieven Bedert, Jan De Backer
European Respiratory Journal Jan 2014, erj00117-2014; DOI: 10.1183/09031936.00011714